SHC

AI Memo

Sotera Health

As of 2026-08-08/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Strong Q2 with raised FY2026 outlook • 2026-08-06

Base target: $20 / p=0% prob

Biggest risk

The positive print may not translate into sustained upside if Nordion's timing benefit normalizes, Nelson Labs cost pressure persists, or leverage remains elevated. Sponsor and CFO dispositions are ownership context only, not evidence of operating weakness [#SEC-FORM4-2026-08-07].

Invalidation

Break below $16 or thesis failure.

What would change my mind?

Raised outlook, high-single-digit growth, strong Sterigenics and Nordion execution, improved liquidity, and leverage reaching the company's 2.0x-3.0x target range support upside if performance persists [#SEC-8K-2026-08-06].

Research note

Recommendation

—

Confidence

high

As of

2026-08-08

Base target

$20

p=0%

Bull target

$24

p=0%

Bear target

$16

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print margin and growth digestion
Execution and deleveraging runway
Raised outlook, high-single-digit growth, strong Sterigenics and Nordion execution, improved liquidity, and leverage reaching the company's 2.0x-3.0x target range support upside if performance persists [#SEC-8K-2026-08-06].

BearKey bullets

Nelson Labs six-month segment income declined 4.9%, with higher costs affecting margins [#SEC-8K-2026-08-06].
Nordion's strong quarterly growth was partly driven by the timing of Cobalt-60 harvests and may be less repeatable [#SEC-8K-2026-08-06].
Post-earnings analyst target, estimate, and rating revisions are unavailable; missing revision evidence should not be treated as positive.

WatchKey bullets

Strong Q2 with raised FY2026 outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $20 (p=0%)

Target spread vs base: +23% / -21%

Scenario probabilities

Bull Target: $24 (p=0%)Base Target: $20 (p=0%)Bear Target: $16 (p=0%)

Commentary

Earnings-related news tone is positive, but coverage is limited and social evidence is unavailable. The August 7 close was $18.86; the packet lacks a clean pre-release comparator and trusted attribution for the immediate market reaction. Post-print analyst revisions are unavailable. The deterministic prior remains negative over 20-120 days, so this is a monitoring-style follow-up rather than a high-conviction bullish signal.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print margin and growth digestion
Execution and deleveraging runway

Scenarios

Bull Target (Scenario probability)

$24 / p=0% prob

Base Target (Scenario probability)

$20 / p=0% prob

Bear Target (Scenario probability)

$16 / p=0% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Strong Q2 with raised FY2026 outlook
Sotera reported Q2 revenue growth of 9.2%, Adjusted EBITDA growth of 10.0%, Adjusted EPS growth of 30%, and raised full-year revenue and Adjusted EBITDA growth outlooks [#SEC-8K-2026-08-06].
Prob 100.00% • Move 4.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Post-print margin and growth digestion
2026-11-06
Nelson Labs delivered 5.4% constant-currency revenue growth, but six-month segment income declined 4.9% and higher costs pressured margins; Nordion growth also benefited partly from Cobalt-60 harvest timing [#SEC-8K-2026-08-06].
Prob 65% • Move -4% • Priced-in 35%

Long-term Catalysts

Months to a year

Execution and deleveraging runway
2027-08-08
Sustained pricing and volume execution at Sterigenics, strong Nordion growth, approximately $950 million of liquidity, 3.0x net leverage, and term-loan repricing savings could support a gradual rerating [#SEC-8K-2026-08-06].
Prob 55% • Move 9% • Priced-in 45%

Risks

Nelson Labs six-month segment income declined 4.9%, with higher costs affecting margins [#SEC-8K-2026-08-06].
Nordion's strong quarterly growth was partly driven by the timing of Cobalt-60 harvests and may be less repeatable [#SEC-8K-2026-08-06].
Post-earnings analyst target, estimate, and rating revisions are unavailable; missing revision evidence should not be treated as positive.
Recent Form 4 activity includes a CFO tax-withholding disposition and earlier sponsor secondary sales; these are ownership signals only [#SEC-FORM4-2026-08-07].
The company reported $2.2 billion of debt and 3.0x net leverage, leaving execution and refinancing sensitivity [#SEC-8K-2026-08-06].

Peers

Symbol	Summary
AMRX	Loose same-sector and market-cap comparator; its pharmaceutical operating model is not directly comparable to Sotera's sterilization, isotope, and laboratory-services mix.
ACAD	Loose same-sector comparator with limited operating read-through; the packet contains no tight direct peer set for Sotera's healthcare-services model.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

AMRX

Loose same-sector and market-cap comparator; its pharmaceutical operating model is not directly comparable to Sotera's sterilization, isotope, and laboratory-services mix.

ACAD

Loose same-sector comparator with limited operating read-through; the packet contains no tight direct peer set for Sotera's healthcare-services model.